• March is National Kidney Month

    March is National Kidney Month
    Help us celebrate this month by participating in our popular 31 Days of PKD Challenges or by making a tribute gift in honor of someone you love.
    Take the 31-day challenge | Honor a loved one with your tribute gift

  • What is PKD?

    What is PKD?
    PKD affects thousands in the United States and millions worldwide — and yet, many people have never heard of it. Play Watch this short video and learn more about this little-known disease.

  • What's New in PKD: A Day of Learning

    What's New in PKD: A Day of Learning
    Listen to PKD experts from across the country discuss topics important to PKD patients. This year we will focus on the different health complications associated with PKD.
    See if your Chapter is participating and register

  • Help Further Our Understanding of PKD

    Help Further Our Understanding of PKD
    We are excited to announce the release of our Request for Applications for two research fellowships. All applications are due by April 1, 2015.
    See if you're eligible and apply today!

PKD News

CHMP Recommends JINARC® (Tolvaptan) for Approval in EU:
The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Feb. 27, 2015

Otsuka Pharmaceutical Co., Ltd. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended JINARC® (tolvaptan) for approval. This treatment has been recommended to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease (CKD) stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.

Read the full press release from Otsuka Pharmaceutical Co., Ltd.

PillsTreatment for ADPKD Approved in Canada

Feb. 26, 2015

JINARC™ (tolvaptan) has been approved in Canada as a treatment for autosomal dominant polycystic kidney disease (ADPKD). JINARC™ was discovered in Japan by Otsuka Pharmaceutical and was first approved there for ADPKD in 2014. The Health Canada approval of JINARC™ is based on the results of the pivotal Phase 3 randomized, double-blind and placebo-controlled TEMPO 3:4 Trial, the largest study conducted to date in adults with ADPKD.

Read more

Voices of PKD

Living with Polycystic Kidney DiseaseMaryKatherine Michiels-Kibler

Five years ago, at age 13, I was diagnosed with polycystic kidney disease (PKD) after a series of visits to the emergency room with severe abdominal pain and vomiting. PKD, which causes cysts to grow on the kidneys, eventually leads to kidney failure and can cause a kidney to weigh up to 30 pounds. I am the youngest person in my family to be diagnosed. PKD is a genetic disease and parents with PKD have a 50 percent chance of passing the disease to each of their children. My mother, grandfather and great grandfather all have PKD.

Not only did I find out I had a genetic disease with no treatment or cure, I also had to learn it was a disease that despite affecting thousands in the U.S. and millions world wide had many unknowns and inconsistencies. While as a young teenager all I wanted to do was ignore this imperfection I realized that because I was diagnosed at such a young age, I had the opportunity to help. Unwilling to accept the feeling of powerlessness when facing PKD my mom and I turned to The PKD Foundation, an organization solely dedicated to finding treatments and a cure for PKD, to get involved in a brighter future for the disease.

Read MaryKatherine's Story